Strata Critical Medical Upgraded to Hold by Zacks Research

Analysts see mixed outlook for the medical device company's stock performance.

Mar. 28, 2026 at 10:51am

Got story updates? Submit your updates here. ›

Strata Critical Medical (NASDAQ:SRTA) was upgraded to a 'hold' rating by Zacks Research on Thursday, with analysts citing a mixed outlook for the medical device company's stock performance.

Why it matters

Strata Critical Medical is a small-cap medical device company that has seen its stock price fluctuate significantly over the past year. The Zacks upgrade signals that analysts see potential upside, but also ongoing challenges that could limit the stock's near-term gains.

The details

In their research note, Zacks analysts cited a combination of positive and negative factors impacting Strata Critical Medical. On the positive side, the company has received some new product approvals and development milestones that could drive future revenue growth. However, analysts also noted ongoing competitive pressures and uncertainty around the company's long-term profitability.

  • Zacks Research issued the upgrade on Thursday, March 28, 2026.

The players

Strata Critical Medical

A small-cap medical device company that develops critical care products.

Zacks Research

An independent equity research firm that provides analysis and ratings on publicly traded companies.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if Strata Critical Medical can capitalize on its recent product approvals and maintain profitability in the face of industry competition.

The takeaway

The Zacks upgrade highlights the challenges facing small-cap medical device companies like Strata Critical Medical, which must balance innovation with operational efficiency to deliver consistent returns for investors.